Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 25.
doi: 10.1002/nau.70098. Online ahead of print.

Interstitial Cystitis/Bladder Pain Syndrome Patient Phenotyping

Dylan T Wolff  1 , Stephen Tranchina  1 , Andrew Schrepf  2 , R Christopher Doiron  3 , Toby C Chai  4 , Stephen J Walker  1   5
Affiliations
Review

Interstitial Cystitis/Bladder Pain Syndrome Patient Phenotyping

Dylan T Wolff et al. Neurourol Urodyn. .

Abstract

Aims: In April of 2025, the Wake Forest Institute for Regenerative Medicine hosted a Global Consensus meeting on IC/BPS in Winston-Salem, NC. The goal of this meeting was to establish global consensus regarding diagnostic criteria, phenotyping, treatment outcome assessment, and etiopathology in interstitial cystitis/bladder pain syndrome (IC/BPS). Our sub-committee was tasked with developing a consensus document on patient phenotyping in IC/BPS.

Methods: Narrative review.

Results: Patients with IC/BPS populate broad groups that have been characterized as having a bladder-focused disease phenotype (bladder-centric), a widespread pain and symptoms phenotype (systemic), or by other variable phenotypes including those with myofascial pelvic pain. In this review, we discuss the published evidence supporting each of these patient phenotypic groups.

Conclusions: Future clinical trials and treatment development in IC/BPS should include patient phenotyping efforts with, at minimum, a focus on stratification into bladder-centric vs systemic and efforts to refine discriminative thresholds (cut-off points) that may influence differential treatment outcomes. It is important to continue to investigate the importance of patient phenotypes on treatment strategy selection, outcomes, and our understanding of the underlying pathophysiology for this disease spectrum.

Clinical trial registration: N/A.

Keywords: consensus; interstitial cystitis/bladder pain syndrome; phenotyping.

PubMed Disclaimer

References

    1. S. H. Berry, M. N. Elliott, M. Suttorp, et al., “Prevalence of Symptoms of Bladder Pain Syndrome/Interstitial Cystitis Among Adult Females in the United States,” Journal of Urology 186, no. 2 (August 2011): 540–544, https://doi.org/10.1016/j.juro.2011.03.132.
    1. A. M. Suskind, S. H. Berry, B. A. Ewing, M. N. Elliott, M. J. Suttorp, and J. Q. Clemens, “The Prevalence and Overlap of Interstitial Cystitis/Bladder Pain Syndrome and Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Men: Results of the RAND Interstitial Cystitis Epidemiology Male Study,” Journal of Urology 189, no. 1 (January 2013): 141–145, https://doi.org/10.1016/j.juro.2012.08.088.
    1. H. H. Lai, N. A. Pickersgill, and J. M. Vetter, “Hunner Lesion Phenotype in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta‐Analysis,” Journal of Urology 204, no. 3 (September 2020): 518–523, https://doi.org/10.1097/JU.0000000000001031.
    1. H. H. Lai, C. Newcomb, S. Harte, et al., “Comparison of Deep Phenotyping Features of UCPPS With and Without Hunner Lesion: A MAPP‐II Research Network Study,” Neurourology and Urodynamics 40, no. 3 (March 2021): 810–818, https://doi.org/10.1002/nau.24623.
    1. R. C. Doiron, V. Tolls, K. Irvine‐Bird, K. L. Kelly, and J. C. Nickel, “Clinical Phenotyping Does Not Differentiate Hunner Lesion Subtype of Interstitial Cystitis/Bladder Pain Syndrome: A Relook at the Role of Cystoscopy,” Journal of Urology 196, no. 4 (October 2016): 1136–1140, https://doi.org/10.1016/j.juro.2016.04.067.

LinkOut - more resources